Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market

Author's Avatar
Apr 05, 2022

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL® (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).